

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4035881

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	NOAM EMANUEL	01/04/2011
RECEIVING PARTY DATA		
Name:	POLYPID LTD.	
Street Address:	P.O. BOX 65098	
City:	TEL-AVIV	
State/Country:	ISRAEL	
PROPERTY NUMBERS Total: 2		
	Property Type	Number
	Patent Number:	9421271
	Application Number:	15244048
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	djf@4d-ip.com	
Correspondent Name:	DANIEL FEIGELSON	
Address Line 1:	7 OPPENHEIMER ST.	
Address Line 4:	REHOVOT, ISRAEL	
ATTORNEY DOCKET NUMBER:	1309801US CON	
NAME OF SUBMITTER:	DANIEL FEIGELSON	
SIGNATURE:	/Daniel Feigelson/	
DATE SIGNED:	09/02/2016	
Total Attachments: 5		
source=PPD-001-US-assignment-of-parent-case#page1.tif		
source=PPD-001-US-assignment-of-parent-case#page2.tif		
source=PPD-001-US-assignment-of-parent-case#page3.tif		
source=PPD-001-US-assignment-of-parent-case#page4.tif		
source=PPD-001-US-assignment-of-parent-case#page5.tif		

ASSIGNMENT

This Assignment is made and executed by:

EMANUEL Noam	NEUMAN Moshe	BARAK Shlomo
5 Hanamer Street	41 Had-Ness Street	32 Elkachi Street
Jerusalem 96954	Ramat-Gan 52331	Tel Aviv 69497
Israel	Israel	Israel

(hereinafter "Assignors"), to and in favor of POLYPID LTD. having a business address of P.O. Box 65098, 61650 Israel (hereinafter "Assignee").

Whereas each of the Assignors desires to assign his entire right, title and interest in and to the invention described in the nonprovisional patent application for a United States Patent entitled "SUSTAINED-RELEASE DRUG CARRIER COMPOSITION" Serial No. 13/003,955 filed on January 13, 2011 (hereinafter the "Patent Application") and all patents, patent applications and the like on the invention to Assignee for valuable consideration; and

Whereas Assignee has provided such valuable consideration to the Assignors;

Accordingly, Assignors each warrant, covenant and agree as follows:

1. Each of the Assignors hereby sells, assigns and conveys to Assignee such Assignor's entire right, title and interest in and to the invention described in the Patent Application, including the Patent Application itself and all substitute, continuation, continuation-in-part and divisional applications based in whole or in part on the Patent Application, and including all patents resulting therefrom and all reissues and extensions thereof, and including any and all rights of priority resulting from the filing of any such applications within the United States.

2. Each of the Assignors hereby sells, assigns and conveys to Assignee such Assignor's entire right, title and interest in all counterparts to the Patent Application that have been or may be filed outside the United States or under the Patent Cooperation Treaty, whether pursued as a patent, an inventor's certificate, a utility model or the like, including all rights of priority based on the Patent Application, further including all continuation, continuation-in-part and divisional applications based in whole or in part on the non-U.S. counterparts, and still further including all patents, inventor's certificates, utility models, reissues and extensions resulting from any of the non-U.S. counterparts.

3. Each of the Assignors hereby grants to Assignee the sole and exclusive right to prosecute the Patent Application and all related applications as described in Paragraphs 1 and 2 above, as well as any opposition proceedings, reissue applications, reexaminations, and nullity or invalidity proceedings. Each of the Assignors authorizes all governmental bodies having the power to issue patents, inventor's certificates or utility models to issue a patent, inventor's

ASSIGNMENT

Title: "SUSTAINED-RELEASE DRUG CARRIER COMPOSITION"

U.S. Serial No.

Docket No. _____

certificate or utility model based on the Patent Application or any related applications as described in Paragraphs 1 and 2 above in the name of Assignee.

4. Each of the Assignors agrees upon request and without further consideration, but at Assignee's expense: (a) to assist Assignee in prosecuting the Patent Application and all related applications as described in Paragraphs 1 and 2 above, as well as opposition proceedings, reissue applications, reexaminations, and nullity or invalidity proceedings; (b) to provide Assignee with information concerning the Patent Application and the related applications described in Paragraphs 1 and 2 above to enable Assignee to obtain, secure and protect all of the rights, title and interest sold, assigned, conveyed and granted under this Assignment (the "Assigned Assets"); (c) to sign papers, take oaths and testify in legal proceedings to enable Assignee to obtain, secure and protect the Assigned Assets; and (d) to perform all acts reasonably necessary to enable Assignee to obtain, secure and protect the Assigned Assets, including assistance in any proceedings pertaining to the Patent Application and the related applications described in Paragraphs 1 and 2 above or to their enforcement.

5. Each of the Assignors warrants and covenants that such Assignor has the full right to sell, assign and convey the Assigned Assets, that all of the Assigned Assets are free and clear of all mortgages, liens, security interests, charges, claims, royalty obligations and encumbrances of any nature whatsoever and that the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

6. Assignee may assign the Assigned Assets in whole or in part. All references herein to Assignee include any successors or assigns of Assignee.

7. Each of the Assignors acknowledges that Assignee has paid valuable consideration for the Assigned Assets.

8. Each of the Assignors hereby authorizes any member of the firm of Rothwell, Figg, Ernst & Manbeck, P.C. to insert or complete any information, including but not limited to the patent application serial number, needed to effect this document's recordation in the United States Patent and Trademark Office.

ASSIGNMENT

Title: "SUSTAINED-RELEASE DRUG CARRIER COMPOSITION"

U.S. Serial No.

Docket No. _____

4/1/11
Date


EMANUEL Noam


Witness

Date

NEUMAN Moshe

Witness

Date

BARAK Shlomo

Witness

ASSIGNMENT
Title: "SUSTAINED-RELEASE DRUG CARRIER COMPOSITION"
U.S. Serial No.

Docket No. _____

Date

EMANUEL Noam

Witness

Date

January 8, 2011

NEUMAN Moshe

Witness

Date

BARAK Shlomo

Witness

ASSIGNMENT
Title: "SUSTAINED-RELEASE DRUG CARRIER COMPOSITION"
U.S. Serial No.

Docket No. _____

Date

EMANUEL Noam

Witness

Date

NEUMAN Moshe

Witness

9.1.2011
Date

13

BARAK Shlomo

Witness